https://assets.capyfin.com/instruments/678fdc13234e27009c5d59e0.png avatar
GE HealthCare
🇺🇸 NASDAQ:GEHC
•
Dec 31, 2024

GE HealthCare Q4 2024 Earnings Report

Key Takeaways

GE HealthCare reported 2.17% revenue growth in Q4 2024, reaching $5.319 billion. Strong performance in Advanced Visualization Solutions and Pharmaceutical Diagnostics drove results, alongside improved operating and net margins. Adjusted earnings per share grew 22.88% year-over-year.

Total Revenue
$5.32B
Previous year: $5.21B
+2.2%
EPS
$1.45
Previous year: $1.18
+22.9%
Book-to-Bill Ratio
1.09
Previous year: 1.05
+3.8%
Total Orders Growth
6%
0
Net Income Margin
13.5%
Previous year: 7.7%
+75.3%
Gross Profit
$2.28B
Previous year: $2.16B
+5.5%
Cash and Equivalents
$2.89B
Previous year: $2.5B
+15.4%
Free Cash Flow
$811M
Previous year: $956M
-15.2%
Total Assets
$33.1B
Previous year: $32.5B
+2.0%

GE HealthCare Revenue

GE HealthCare EPS

GE HealthCare Revenue by Segment

Forward Guidance

GE HealthCare expects 2%-3% organic revenue growth in 2025, with margin expansion and adjusted EPS growth of 3%-6%. The company will continue investing in innovation and operational efficiency.

Positive Outlook

  • Expected 2%-3% organic revenue growth
  • Adjusted EBIT margin expansion of 40-50 basis points
  • Adjusted EPS growth of 3%-6%
  • Sustained demand in Pharmaceutical Diagnostics and Advanced Visualization
  • Investment strategy in AI and advanced diagnostics

Challenges Ahead

  • Impact of tariffs on products from China
  • Ongoing market weakness in China
  • Inflationary pressures on operating costs
  • Higher financing costs due to interest rates
  • Increasing competition in the medical diagnostics sector

Revenue & Expenses

Visualization of income flow from segment revenue to net income